Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow INTS by emailGet an email when INTS pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about INTS, unsubscribe in one click. Privacy
📣 What INTS Says Is Next
second half of 2026 · “While early, we are pleased with the interest expressed in our science and clinical trials, and we expect to continue discussions in the second half of 2026.” Second Quarter 2026 Financial Results Research and development expenses were $1.8 million for the second quarter of 2026, compared with $1.5 million for the same period in 2025.”
Company press release, Aug 11, 2026 · SEC filing
by the end of 2027 · “In July 2026, the Company restarted patient treatment in the INVINCIBLE-4 Study and is currently targeting complete enrollment by the end of 2027.”
Company press release, Aug 11, 2026 · SEC filing
by the end of 2026 · “The Company is targeting to complete enrollment by the end of 2026 and will likely add resources to help sites enroll.”
Company press release, Nov 6, 2025 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full INTS picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for INTS and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.